AVOCA STREET MEDICAL CENTRE
130 Avoca Street Randwick NSW 2031
Tel: 02 9399 3335 - Fax: 02 9399 9778

avocastreet.com - asmc.net.au - randwickhealth.com - randwickgp.com - familydoctor.sydney

Message from your GPs


Angela


Kien


We are open our usual hours.

In the interests of patient and staff safety, only vaccinated patients will be seen in-person at the practice. If you have not yet obtained your vaccination, we can look after you via telehealth.

If you have any symptoms including sore throat, fever, cough or runny nose, please call and book a telehealth consult.

Children under 12 will be seen as required (accompanying parents must be fully vaccinated).

We will continue to run vaccination clinics under strict settings.

Stay safe, and do call 93993335 if you have further enquiries.

Mandy


Priscilla

Our reception is low on staff. Please be patient.
Thank you for your understanding.
SURGERY HOURS
MON - FRI7:30 AM - 5:30 PM
SATsee notes
SUN & PUBLIC HOLIDAYSCLOSED
Tuesday 18 January 2022
Dr Kien1 PM - 5 PM
Dr Angela8 AM - 12 PM
Dr Mandy10 AM - 1 PM
Dr Priscilla2 PM - 6 PM

We are OPEN

Please call 02 9399 3335 to speak to our reception.


eastvax.com jabmenow.com

To book your next Pfizer COVID-19 vaccination

please visit our

VACCINATION REQUEST & CONSENT PAGE



Dr Priscilla will be on duty on
1st and 3rd Saturdays of each month.
Dr Priscilla is away on holiday until 10 Jan 2022.



NB: Unvaccinated patients can consult only by telephone or video conference calls.

01/01/2022

© smh.com.au



Covid-19 Notices
Emergency Numbers
After Hours 13 74 25
Appointments
Contact
Hours
Doctors
Fees
About
Home
Map
Links
Flu Shot
Immunisation
Facebook
Feedback
Local Pharmacies
Resources

General Information
 

COVID vaccines

Who will be eligible to receive the vaccine?

The COVID-19 vaccination will be free for:

* all Medicare-eligible Australians
* all visa-holders, excluding visa sub-classes 771 (Transit), 600 (Tourist stream), 651 (eVisitor) and 601 (Electronic Travel Authority).

While the Australian Government strongly supports immunisation it is not mandatory and individuals may choose not to vaccinate.

PhaseEligible populations
1aQuarantine and border workers
Frontline healthcare worker sub-groups for prioritisation
Aged care and disability care staff
Aged care and disability care residents
1b Elderly adults aged 80 years and over
Elderly adults aged 70-79 years
Other health care workers
Aboriginal and Torres Strait Islander people > 55
Younger adults with an underlying medical condition, including those with a disability
Critical and high risk workers including defence, police, fire, emergency services and meat processing
2aAdults aged 60-69 years
Adults aged 50-59 years
Aboriginal and Torres Strait Islander people 18- 54
Other critical and high risk workers
2b Balance of adult population
3 Under 18 year olds if recommended


Vaccination locations

Vaccination locations will be established across metropolitan, regional, rural and remote Australia.
Around 30-50 locations will be established as ongoing 'Hospital Hubs' in urban and rural Australia. The sites of these are being finalised in conjunction with States and Territories. They will manage cold chain storage and Pfizer vaccine only and will provide a distribution hub for hospital, quarantine and border staff and residential aged care and disability residents and staff.
A further 1000+ locations will manage and distribute the AstraZeneca vaccine. These sites will include GP Respiratory clinics, general practices, state/territory vaccination clinics and Aboriginal Controlled Health Organisation clinics. These locations will be determined via an expression of interest process which will be open shortly.

Vaccine types


  1. Pfizer/BioNTech Vaccine
    If the vaccine is proven to be safe and effective, and is approved for use, it will be available from early 2021. This vaccine is currently being rolled out across the United Kingdom (UK), european Union (EU) and and the United States of America (USA).
    Administration: 2 doses will be required approximately one month apart
    Side effects: In the trials, the vaccine was generally well-tolerated, and an independent data monitoring committee reported no serious safety concerns. The worst side effects were fatigue and headaches after the second dose. Around four per cent of people reported fatigue and two per cent a headache. Other side effects were pain at the injection site and myalgia.
    With the roll out of the vaccine in the UK, there have been reports of two people with a history of allergies who have had serious adverse reactions to the vaccine. These are being investigated to determine causality.
    Storage: For long-term storage (approximately six months) the vaccine must be kept at -70 C, which requires specialist cooling equipment. Pfizer has a distribution container that keeps the vaccine at that temperature for 10 days if unopened. These containers can be used for temporary storage in a vaccination facility for up to 30 days if they are replenished with dry ice every five days. Once thawed, the vaccine can be stored at 2C to 8C for up to five days.
    General comments:
    It is still unclear if the vaccine provides immunity for the disease as well as preventing infection.
    In the UK, roll out to pregnant women and children is not included due to lack of testing in these groups.
    Early data has been provided to the TGA and there be will be an application for provisional approval for use in Australia.
    The 10 million doses secured by Australia will be manufactured in the United States of America, Belgium and Germany.

  2. University of Oxford/AstraZeneca vaccine
    If the vaccine is proven to be safe and effective, and is approved for use, it will be available from early 2021.
    Administration: Based on current trials it is likely two doses will be required approximately one month apart
    Side effects: Side effects have been reported as minimal, however, there appears to be limited information on what these side effects are
    Storage: The vaccine can be stored at temperatures between 2C to 8C
    General comments:
    Early trials suggest the vaccine may prevent asymptomatic infection, however, more research is required before this can be verified.
    Australia has secured the delivery of 3.8 million doses in early 2021 and 30 million doses will be manufactured in Australia by the Commonwealth Serum Laboratories (CSL).

www.racgp.org.au

The information in the above were collected from the internet,
either from government websites or from reasonably reliable health information sources.
They are for general information only and should not replace the need of seeking medical care during illnesses.

©avocastreet.com